Timothy Iveson

30.8k total citations · 7 hit papers
117 papers, 17.1k citations indexed

About

Timothy Iveson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Timothy Iveson has authored 117 papers receiving a total of 17.1k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 39 papers in Surgery. Recurrent topics in Timothy Iveson's work include Colorectal Cancer Treatments and Studies (63 papers), Gastric Cancer Management and Outcomes (47 papers) and Colorectal Cancer Surgical Treatments (27 papers). Timothy Iveson is often cited by papers focused on Colorectal Cancer Treatments and Studies (63 papers), Gastric Cancer Management and Outcomes (47 papers) and Colorectal Cancer Surgical Treatments (27 papers). Timothy Iveson collaborates with scholars based in United Kingdom, United States and Japan. Timothy Iveson's co-authors include David Cunningham, M. Nicolson, F. Lofts, Stephen Falk, J.H. Scarffe, A. Norman, David B. Smith, Monica Verma, Simon Weeden and J N Thompson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Timothy Iveson

115 papers receiving 16.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2006 4.5k citations David Cunningham, William Allum et al. New England Journal of Medicine profile →
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

2010 3.0k citations Juan W. Valle, David Cunningham et al. New England Journal of Medicine profile →
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

2000 2.5k citations David Cunningham, Timothy Iveson et al. profile →
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

2008 1.7k citations David Cunningham, Naureen Starling et al. New England Journal of Medicine profile →
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Guillem Argilés, Josep Tabernero et al. Annals of Oncology profile →
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 691 citations Andrew Webb, David Cunningham et al. Journal of Clinical Oncology profile →
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Thomas K. Waddell, Ian Chau et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Timothy Iveson

Since Specialization

Citations

This map shows the geographic impact of Timothy Iveson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Iveson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Iveson more than expected).

Fields of papers citing papers by Timothy Iveson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Iveson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Iveson. The network helps show where Timothy Iveson may publish in the future.

Co-authorship network of co-authors of Timothy Iveson

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Iveson. A scholar is included among the top collaborators of Timothy Iveson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Iveson. Timothy Iveson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer 2024 ·Cell Reports Medicine ·(unknown), Faiz Jabbar, (unknown), (unknown), (unknown), Andrea Harkin, Timothy Iveson, Mark Saunders, Rachel Kerr, (unknown), Noori Maka, Jennifer Hay, Joanne Edwards, Ian Tomlinson, Owen J. Sansom, Caroline Kelly, Francesco Pezzella, David Kerr, Alistair Easton, Enric Domingo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
2	Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme 2020 ·BMC Cancer ·Timothy Iveson, Angela M. Carter, Kai‐Keen Shiu, (unknown), Daniel Stevens, Saifee Mullamitha	4
3	Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer 2020 ·JNCI Cancer Spectrum ·Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, (unknown), Niall C. Tebbutt, (unknown), Andrea Harkin, Eva Segelov, Andrew Haydon, Timothy Iveson, Martin R. Stockler	4
4	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer 2020 ·British Journal of Cancer ·(unknown), Antonia K. Roseweir, Kathryn A.F. Pennel, Hester C. van Wyk, Arfon Powell, Donald C. McMillan, Paul G. Horgan, Caroline Kelly, Jennifer Hay, Owen J. Sansom, Andrea Harkin, Campbell S.D. Roxburgh, Janet Graham, David N. Church, Ian Tomlinson, Mark Saunders, Timothy Iveson, Joanne Edwards, James H. Park	14
5	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2020 ·Annals of Oncology ·Guillem Argilés, Josep Tabernero, Roberto Labianca, Daniel Hochhauser, Ramón Salazar, Timothy Iveson, Pierre Laurent‐Puig, Philip Quirke, Takayuki Yoshino, Julien Taı̈eb, Erika Martinelli, Dirk Arnold	736
6	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer 2020 ·The Journal of Pathology Clinical Research ·Antonia K. Roseweir, James H. Park, Sanne ten Hoorn, Arfon Powell, (unknown), Campbell SD Roxburgh, Donald McMillan, Paul G. Horgan, Elizabeth J. Ryan, Kieran Sheahan, Louis Vermeulen, James Paul, Andrea Harkin, Janet Graham, Owen J. Sansom, David N. Church, Ian D. Tomlinson, Mark Saunders, Timothy Iveson, Joanne Edwards	12
7	A new prognostic and predictive tool for shared decision making in stage III colon cancer 2020 ·European Journal of Cancer ·Alberto Sobrero, Alberto Puccini, Qian Shi, Axel Grothey, Thierry André, Anthony F. Shields, Ioannis Souglakos, Takayuki Yoshino, Timothy Iveson, Marcello Ceppi, Paolo Bruzzi	33
8	Adjuvant chemotherapy in colon cancer: state of the art and future perspectives 2020 ·Current Opinion in Oncology ·Timothy Iveson	9
9	Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). 2019 ·Journal of Clinical Oncology ·Timothy Iveson, Alberto F. Sobrero, Takayuki Yoshino, (unknown), Fang‐Shu Ou, (unknown), Qian Shi, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels Henrik Holländer, Valter Torri, Kentaro Yamazaki, Vassilis Georgoulias, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul	27
10	The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? 2018 ·Annals of Oncology ·Alberto Sobrero, Axel Grothey, Timothy Iveson, Roberto Labianca, Takayuki Yoshino, Julien Taı̈eb, Tim Maughan, Marc Buyse, Thierry André, Jeffrey A. Meyerhardt, Anthony F. Shields, Ioannis Souglakos, J.-Y. Douillard, Andrés Cervantes	27
11	Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial 2017 ·Annals of Oncology ·John Bridgewater, S. Pugh, Amy Whitehead, Louise Stanton, Zina Eminton, J. M. MELLOR, (unknown), Meg Finch-Jones, S. Falk, Timothy Iveson, M. Rees, Juan W. Valle, Joanne Hornbuckle, Tamas Hickish, David Cunningham, Tim Maughan, James Garden, Gareth Griffiths, John Primrose	3
12	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) 2017 ·Annals of Oncology ·Axel Grothey, Alberto Sobrero, Jeffrey A. Meyerhardt, Takayuki Yoshino, James Paul, Julien Taı̈eb, Ioannis Souglakos, Richard Kerr, Roberto Labianca, Anthony F. Shields, Franck Bonnetain, Takeharu Yamanaka, I. Boukovinas, Qian Shi, (unknown), Donna Niedzwiecki, Valter Torri, Daniel J. Sargent, Thierry André, Timothy Iveson	3
13	Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer 2017 ·Annals of Oncology ·Timothy Iveson, Rachel Kerr, Mark Saunders, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, (unknown), Andrea Harkin, Claire Scudder, Kathleen Boyd, Ashita Waterston, Louise Medley, Carlene Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, (unknown), James Paul	1
14	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer 2017 ·World Journal of Gastrointestinal Oncology ·Michael Davidson, Ian Chau, David Cunningham, Komel Khabra, Timothy Iveson, Tamas Hickish, Michel Seymour, Naureen Starling	5
15	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial breakdown → 2013 ·The Lancet Oncology ·Thomas K. Waddell, Ian Chau, David Cunningham, David González, Alicia Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Y. Coxon, David A. Smith, Justin S. Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbáchano	547
16	The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials 2009 ·Annals of Oncology ·Ian Chau, A. Norman, David Cunningham, J. Oates, Robert D. Hawkins, Timothy Iveson, M. Nicolson, Peter Harper, Michel Seymour, Tamas Hickish	40
17	Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials 2006 ·European Journal of Cancer ·(unknown), Paul J. Ross, David Cunningham, Alyson Norman, Robert D. Hawkins, Michel Seymour, Peter Harper, Timothy Iveson, M. Nicolson, Tamas Hickish	74
18	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer breakdown → 2006 ·New England Journal of Medicine ·David Cunningham, William Allum, Sally Stenning, J N Thompson, Cornelis J.�H. van de Velde, M. Nicolson, J.H. Scarffe, F. Lofts, Stephen Falk, Timothy Iveson, David B. Smith, Ruth E. Langley, Monica Verma, Simon Weeden, Yu Jo Chua	4494
19	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer 2005 ·Annals of Oncology ·Ian Chau, A. Norman, David Cunningham, Diana Tait, Paul J. Ross, Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, Duncan I. Jodrell, Andrew Webb, J. Oates	135
20	Pulmonary Tumour Emboli: A Difficult Ante-Mortem Diagnosis 2000 ·Clinical Oncology ·(unknown), (unknown), Timothy Iveson	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact